AOI Biosciences Raises Approx. 500 Million Yen to Accelerate Global Expansion of Fertility Testing and Quantum Drug Discovery
Overview of Funding
AOI Biosciences Inc. has raised approximately 500 million yen in total through a third-party allotment of shares and secondary share transactions. This latest round brings the company's cumulative funding to approximately 1 billion yen. The round saw participation from existing investors including Japan Venture Capital, SBI Shinsei Corporate Investment, and i-nest capital, alongside several new investors such as GoAhead Ventures, Seihou Investment Works, SUMISEI INNOVATION FUND, SBI Okasan Alternative Investment, BIG Impact, and Chuo-Shinsei Venture Capital.
Business Overview of AOI Biosciences
Headquartered in Ibaraki City, Osaka Prefecture, AOI Biosciences is a biotech startup operating under the mission of realizing "a world where people's fundamental health is never compromised." The company currently focuses on two core pillars: a diagnostics business centered around the "Beta-2-Glycoprotein I (beta2GPI) Neoself Antibody Test," which elucidates the causes of recurrent pregnancy loss, and the research and development of "allosteric drug discovery technology" leveraging quantum-related technologies in collaboration with Toshiba Corporation.
Purpose of Funding and Future Outlook
The newly raised funds will be primarily allocated toward three key initiatives:
- Accelerating the domestic adoption of the "beta2GPI Neoself Antibody Test" and its global expansion, with a primary focus on Asia.
- Expanding research and development for novel tests and drug discovery targeting autoimmune diseases.
- Increasing R&D investments in the allosteric drug discovery platform utilizing quantum-related technology (SQBM+).
The company's Neoself Antibody Test has already been approved as Advanced Medical Care A, and clinical studies have reported an improved live birth rate in the treatment-administered group, establishing a solid operational foundation for the business.